Skip to main content
Premium Trial:

Request an Annual Quote

AxCell and Celgene Collaborate on Ubiquitin Ligases

NEW YORK, Jan. 22-Cytogen subsidiary AxCell Biosciences will collaborate with Celgene to study the role of ubiquitin ligases in cancer and inflammation, Cytogen said today.

 

The two companies will investigate these compounds, which tag excess or damaged proteins for degradation, as potential treatments for cancer and inflammatory disease.

 

Financial specifics of the research collaboration were not disclosed.

 

Celgene has a portfolio of previously unknown ubiquitin ligases, and is studying small molecule regulators of these molecules.